Country/Region

Doctors Without Borders is urging law makers to revise a provision in the U.S. health care legislation that would essentially allow pharmaceutical companies to extend their monopolies on a rapidly expanding and high-priced brand of drugs known as biologics. Biologics--medicines derived from living cells--hold great promise for new vaccines and medicines. Unfortunately, the biologics provision in the current legislation will create a massive barrier to developing generic versions of these cutting-edge drugs.

More >

A Speech by Dr. Christophe Fournier, MSF's International Council President, given at a NATO gathering in Germany

More >

Falling through the Cracks: The Mounting Health Crisis amid Situations of Precarious Stability

Statement by Sophie Delaunay, Executive Director Médecins Sans Frontières

On behalf of Médecins Sans Frontières (MSF), I would like to thank the President of the Economic and Social Council for the opportunity to speak on the important topic of “health challenges in post-crisis situations.”

More >

Statement by Sophie Delaunay Executive Director, MSF-USA

This annual Ministerial review focusing on philanthropy and the Global Health Agenda clearly shows recognition of the urgency to address global health challenges. However, this initiative cannot replace the critical need for greater government leadership to stimulate medical innovation for neglected diseases affecting millions in the poorest corners of the world.

More >


MSF official statement

Once again in this type of situation, there is a lot of confusion introduced, whether deliberately or through a lack of correct information, between the role of the states that have ratified the statute of the International Criminal Court (ICC), the United Nations, and the activities of independent humanitarian organizations such as Doctors Without Borders/Médecins Sans Frontières (MSF).

More >

Before the High Level task force communicates its first Comprehensive Framework for Action, Médecins Sans Frontières urges careful consideration of the population that is most vulnerable to the dire consequences of malnutrition – children under two.

More >

My name is Dr. Tido von Schoen-Angerer and I am speaking on behalf of Médecins Sans Frontières. Thank you for the opportunity to address this important gathering.

In 2000, I was working in one of MSF’s AIDS projects. Our response to the pandemic was one based on a simple medical decision: faced with the urgency of patients dying, the only acceptable response was to treat. This was an ethical imperative, to treat, regardless of the difficulties.

More >

U.S congressional briefing delivered by Dr. Buddhima Lokuge, U.S. Manager of MSF's Campaign for Access to Essential Medicines on Thailand's compulsory drug licensing.

More >

Presentation by Fabrice Weissman, MSF Foundation and former Head of Mission for MSF in Darfur, Sudan to Panel Discussion at Columbia University School of International and Public Affairs

More >

Dear Mr. White, We are writing to you to express our concern about the lack of availability in developing countries of the new melt extrusion (Meltrex) formulation of lopinavir/ritonavir (LPV/r), marketed as Kaletra (200/50mg tablets).

More >

Pages